These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35452622)

  • 21. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
    Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
    Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
    Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Chang Y; Sutherland A; Montefiori DC; Girard B; Edwards DK; Feng J; Zhou H; Baden LR; Miller JM; Das R
    N Engl J Med; 2022 Oct; 387(14):1279-1291. PubMed ID: 36112399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.
    Evans JP; Zeng C; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
    Sci Transl Med; 2022 Mar; 14(637):eabn8057. PubMed ID: 35166573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.
    Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
    bioRxiv; 2022 Sep; ():. PubMed ID: 36263060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice.
    Slamanig S; González-Domínguez I; Chang LA; Lemus N; Lai TY; Martínez JL; Singh G; Dolange V; Abdeljawad A; Kowdle S; Noureddine M; Warang P; Singh G; Lee B; García-Sastre A; Krammer F; Schotsaert M; Palese P; Sun W
    EBioMedicine; 2024 Jul; 105():105185. PubMed ID: 38848648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects.
    Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M
    Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
    Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
    Chalkias S; McGhee N; Whatley JL; Essink B; Brosz A; Tomassini JE; Girard B; Edwards DK; Wu K; Nasir A; Lee D; Avena LE; Feng J; Deng W; Montefiori DC; Baden LR; Miller JM; Das R
    J Infect Dis; 2024 Aug; 230(2):e279-e286. PubMed ID: 38349280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
    Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
    Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice.
    Shin KS; Kim BS; Chang S; Jung IK; Park H; Park S; Shin J; Kim JH; Han SJ; Park B; Kim JO; Lee JA; Lee TY; Kang CY
    Int J Antimicrob Agents; 2024 Mar; 63(3):107082. PubMed ID: 38163552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants.
    Belik M; Jalkanen P; Lundberg R; Reinholm A; Laine L; Väisänen E; Skön M; Tähtinen PA; Ivaska L; Pakkanen SH; Häkkinen HK; Ortamo E; Pasternack A; Ritvos MA; Naves RA; Miettinen S; Sironen T; Vapalahti O; Ritvos O; Österlund P; Kantele A; Lempainen J; Kakkola L; Kolehmainen P; Julkunen I
    Nat Commun; 2022 May; 13(1):2476. PubMed ID: 35513437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
    Munoz FM; Posavad CM; Richardson BA; Badell ML; Bunge KE; Mulligan MJ; Parameswaran L; Kelly CW; Olson-Chen C; Novak RM; Brady RC; Pasetti MF; Defranco EA; Gerber JS; Shriver MC; Suthar MS; Coler RN; Berube BJ; Kim SH; Piper JM; Miller AM; Cardemil CV; Neuzil KM; Beigi RH;
    Vaccine; 2023 Aug; 41(36):5296-5303. PubMed ID: 37451878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters.
    Halfmann PJ; Kuroda M; Maemura T; Chiba S; Armbrust T; Wright R; Balaram A; Florek KR; Bateman AC; Kawaoka Y
    Cell Rep; 2022 Apr; 39(3):110688. PubMed ID: 35421378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.